-

Bausch + Lomb Will Participate at the 2023 Wells Fargo Healthcare Conference

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman and CEO Brent Saunders is scheduled to participate at the 2023 Wells Fargo Healthcare Conference in Boston on Sept. 6, 2023, at 10:15 a.m. ET.

A live webcast and audio archive of the conference will be available on the Investor Relations section of the Bausch + Lomb website.

About Bausch + Lomb

Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from the moment of birth through every phase of life. Its comprehensive portfolio of more than 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario with corporate offices in Bridgewater, New Jersey. For more information, visit www.bausch.com and connect with us on Twitter, LinkedIn, Facebook and Instagram.

© 2023 Bausch + Lomb.

Contacts

Media Contacts:
T.J. Crawford
tj.crawford@bausch.com
(908) 705-2851

Lainie Keller
lainie.keller@bausch.com
(908) 927-1198

Investor Contacts:
George Gadkowski
george.gadkowski@bausch.com

Allison Ryan
allison.ryan@bausch.com
(877) 354-3705 (toll free)
(908) 927-0735

Industry:

Bausch + Lomb Corporation

NYSE:BLCO
Release Versions
English

Contacts

Media Contacts:
T.J. Crawford
tj.crawford@bausch.com
(908) 705-2851

Lainie Keller
lainie.keller@bausch.com
(908) 927-1198

Investor Contacts:
George Gadkowski
george.gadkowski@bausch.com

Allison Ryan
allison.ryan@bausch.com
(877) 354-3705 (toll free)
(908) 927-0735

More News From Bausch + Lomb Corporation

Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company, and its parent company, Bausch Health Companies Inc. (NYSE/TSX: BHC), today announced that Bausch + Lomb Board of Directors Chairman Thomas J. Appio has been appointed interim chief executive officer, effective immediately. Appio will continue to serve as CEO of Bausch Health while assuming leadership of Bausch + Lomb. Appio was appointed chairman of the Bausch + Lomb Board of Dir...

Bausch + Lomb Advances Novel Oral Treatment for Dry AMD Following Constructive FDA Meeting

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced progress in the development of BL1243 (tonabersat), an investigational oral treatment for dry age-related macular degeneration (AMD), following a constructive meeting with the U.S. Food and Drug Administration (FDA). The discussion provided greater clarity on the clinical development path for BL1243. If successf...

Bausch + Lomb Will Release Third-Quarter 2026 Financial Results on Oct. 28

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its third-quarter financial results on Wednesday, Oct. 28, 2026. The company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the c...
Back to Newsroom